Biogen Alzheimer's drug data falls flat, Lilly gets slight bump

July 22 (Reuters) - Disappointing data for Biogen Inc's experimental Alzheimer's drug dragged shares in the company lower on Wednesday, while investors took a slightly more positive view of new findings for a treatment from Eli Lilly and Co.